Q-TWiST analysis of tivozanib (T) versus sorafenib (S) in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study.

被引：0

作者：

Szarek, Michael ^{[1
]}

Needle, Michael N. ^{[2
]}

Rini, Brian, I ^{[3
]}

Pal, Sumanta K. ^{[4
]}

McDermott, David F. ^{[5
]}

Atkins, Michael B. ^{[6
]}

Hutson, Thomas E. ^{[7
]}

Escudier, Bernard ^{[8
]}

机构：

[1] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA

[2] Aveo Oncol, Boston, MA USA

[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[4] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA

[5] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA

[6] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[7] Texas A&M Coll Med, Bryan, TX USA

[8] Gustave Roussy, Villejuif, France

来源：

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.298

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

298

引用

页数：2